Pregabalin
Pregabalin.JPG

CLINICAL USE

Anti-epileptic agent Neuropathic pain Generalised anxiety disorder

DOSE IN NORMAL RENAL FUNCTION

150–600 mg daily in 2 or 3 divided doses

PHARMACOKINETICS

  • Molecular weight                           :159.2
  • %Protein binding                           :0
  • %Excreted unchanged in urine     : 92–99
  • Volume of distribution (L/kg)       :0.56
  • half-life – normal/ESRD (hrs)      :5–6.5/ Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–60 Initial dose 75 mg daily and titrate according to tolerability and response15–30 Initial dose 25–50 mg daily and titrate according to tolerability and response<15 Initial dose 25 mg daily and titrate according to tolerability and response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in GFR<15 mL/min
  • HD                     :Dialysed. Dose as in GFR<15 mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR<15 mL/min
  • CAV/VVHD      :Dialysed. Dose as in GFR=15–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Oral bioavailability >90% 50% of dose is removed after a 4 hour haemodialysis sessionUse with caution in people with severe congestive heart failure. May cause reversible deterioration in renal function.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs